MOG and myeloid sarcoma: In MS treatment, SAC per os administration, at 50 mg/kg/day, in MOG induced female mice, showed clinical signs and severity alleviation, with TNF-alpha, IL-17 and MMP-9 reduction, and activity-dependent neuroprotector homeobox (ADNP) and microtubule-associated proteins 1A/1 B increase [121].